http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 29 Jun 2026 06:14:57 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Investing/Sandoz+submits+generic+obesity+drug+applications+to+FDA/26701558.html <p>Investing.com -- Sandoz has submitted two generic versions of tirzepatide to the U.S. Food and Drug Administration for review. The drugs would compete with Eli Lilly's obesity and diabetes treatments Mounjaro and Zepbound if approved.</p><p>The Swiss generics drugmaker said the proposed medications would treat type-2 diabetes and weight management, matching the same conditions as Eli Lilly's branded products. Eli Lilly's tirzepatide patent expires in 2036 in the United States.</p><p>"Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the U.S. on market formation," the company said in a statement.</p><p>The FDA has not indicated how long http://www.streetinsider.com/Investing/Sandoz+submits+generic+obesity+drug+applications+to+FDA/26701558.html Mon, 29 Jun 2026 06:14:57 -0400 LLY NVO SDZNY http://www.streetinsider.com/Investing/Sandoz+submits+generic+obesity+drug+applications+to+FDA/26701558.html <p>Investing.com -- Sandoz has submitted two generic versions of tirzepatide to the U.S. Food and Drug Administration for review. The drugs would compete with Eli Lilly's obesity and diabetes treatments Mounjaro and Zepbound if approved.</p><p>The Swiss generics drugmaker said the proposed medications would treat type-2 diabetes and weight management, matching the same conditions as Eli Lilly's branded products. Eli Lilly's tirzepatide patent expires in 2036 in the United States.</p><p>"Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the U.S. on market formation," the company said in a statement.</p><p>The FDA has not indicated how long http://www.streetinsider.com/Investing/Sandoz+submits+generic+obesity+drug+applications+to+FDA/26701558.html Mon, 29 Jun 2026 06:14:57 -0400 LLY NVO SDZNY http://www.streetinsider.com/Investing/Sandoz+submits+generic+obesity+drug+applications+to+FDA/26701558.html <p>Investing.com -- Sandoz has submitted two generic versions of tirzepatide to the U.S. Food and Drug Administration for review. The drugs would compete with Eli Lilly's obesity and diabetes treatments Mounjaro and Zepbound if approved.</p><p>The Swiss generics drugmaker said the proposed medications would treat type-2 diabetes and weight management, matching the same conditions as Eli Lilly's branded products. Eli Lilly's tirzepatide patent expires in 2036 in the United States.</p><p>"Sandoz tirzepatide could be one of the first generic tirzepatide products available for patients in the U.S. on market formation," the company said in a statement.</p><p>The FDA has not indicated how long http://www.streetinsider.com/Investing/Sandoz+submits+generic+obesity+drug+applications+to+FDA/26701558.html Mon, 29 Jun 2026 06:14:57 -0400 LLY NVO SDZNY http://www.streetinsider.com/Hot+List/Why+Kepler+says+this+pharma+stock+is+%27one-of-a-kind+investment+opportunity%27/25848785.html <p>One European drugmaker is viewed by Kepler analysts as a “one-of-a-kind investment opportunity,” driven by unusually strong visibility on patent expiries and a pipeline that stretches well into the next decade. </p><p>Following a recent industry update in San Francisco, analyst Nicolas Pauillac said the company reinforced its long-term investment case by clearly mapping out how it plans to monetise a wave of loss-of-exclusivity events (LOEs) across generics and biosimilars.</p><p>The company Pauillac is referring to is Swiss generic drug manufacturer Sandoz (OTC: SDZNY).</p><p>After attending the event, the analyst highlighted Sandoz’s “very confident management team,” which provided additional detail on the scale http://www.streetinsider.com/Hot+List/Why+Kepler+says+this+pharma+stock+is+%27one-of-a-kind+investment+opportunity%27/25848785.html Wed, 14 Jan 2026 12:00:00 -0400 SDZNY http://www.streetinsider.com/Hot+List+Pro/Why+Kepler+says+this+pharma+stock+is+%27one-of-a-kind+investment+opportunity%27/25848785.html <p>One European drugmaker is viewed by Kepler analysts as a “one-of-a-kind investment opportunity,” driven by unusually strong visibility on patent expiries and a pipeline that stretches well into the next decade. </p><p>Following a recent industry update in San Francisco, analyst Nicolas Pauillac said the company reinforced its long-term investment case by clearly mapping out how it plans to monetise a wave of loss-of-exclusivity events (LOEs) across generics and biosimilars.</p><p>The company Pauillac is referring to is Swiss generic drug manufacturer Sandoz (OTC: SDZNY).</p><p>After attending the event, the analyst highlighted Sandoz’s “very confident management team,” which provided additional detail on the scale http://www.streetinsider.com/Hot+List+Pro/Why+Kepler+says+this+pharma+stock+is+%27one-of-a-kind+investment+opportunity%27/25848785.html Wed, 14 Jan 2026 12:00:00 -0400 SDZNY http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Press+Releases/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html <ul class="bwlistdisc"> <li> Expands access to much-needed iron therapy for millions of US patients </li> <li> Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches </li> <li> Strengthens US supply of injectable iron sucrose </li> </ul> <p> PRINCETON, N.J.--(BUSINESS WIRE)-- Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA)1. The product is now available for order and delivery across the United States. The launch of this iron sucrose formulation further expands the Sandoz US iron therapy portfolio. </p><p> Intravenous iron sucrose is http://www.streetinsider.com/Business+Wire/Sandoz+launches+affordable+iron+sucrose+injection+for+treatment+of+iron+deficiency+anemia+in+patients+with+chronic+kidney+disease+in+US/25372073.html Wed, 24 Sep 2025 16:15:00 -0400 A.06822034 A.16030647 A.17792863 A.30142833 A.32437804 O.00003102 O.00162576 O.00513499 O.20026344 O.34978779 O.53134629 SDZ SDZNY